Shaperon Inc. Logo

Shaperon Inc.

Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.

378800 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 강남구 자곡로 174-10 강남에이스타워 606호(자곡동), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shaperon Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory diseases and cancer. The company specializes in creating innovative inflammasome inhibitors, utilizing a unique mechanism of action involving GPCR19-P2X7 modulation to suppress immune responses. Its development pipeline targets conditions such as atopic dermatitis and other immune-mediated inflammatory disorders. In addition to small molecules, Shaperon develops nanobody therapeutics for cancer immunotherapy, leveraging proprietary immunized libraries and high-throughput screening technologies. Founded in 2008, the company completed a successful initial public offering in October 2022.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Shaperon Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.0 KB
2025-09-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-09-16 00:00
Share Issue/Capital Change
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean 7.6 KB
2025-09-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 40.4 KB
2025-09-16 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 435.2 KB
2025-09-16 00:00
Prospectus
투자설명서
Korean 2.7 MB
2025-09-16 00:00
Share Issue/Capital Change
권리락 (유상증자)
Korean 3.5 KB
2025-09-12 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 42.6 KB
2025-09-01 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.2 MB

Automate Your Workflow. Get a real-time feed of all Shaperon Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Shaperon Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea 206650
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France EAPI
Eurobio Scientific Logo
Develops & distributes specialty IVD tests for oncology, transplant & infectious diseases.
France ALERS
European Institute of Science AB Logo
Manufactures diagnostic assays and point-of-care instruments for the veterinary health market.
Sweden EURI B
ExpreS2ion Biotech Holding AB Logo
Clinical-stage biotech developing vaccines and immunotherapies via a proprietary protein platform.
Sweden EXPRS2
EyeGene,Inc Logo
Develops gene/cell therapies & mRNA vaccines for age-related and ocular diseases.
South Korea 185490
Faes Farma S.A. Logo
Develops and markets pharmaceuticals, like antihistamines, and animal nutrition products globally.
Spain FAE
Fagron N.V. Logo
Supplies compounding ingredients and solutions for personalized medicine to healthcare professionals.
Belgium FAGR
Farmak Logo
A pharmaceutical manufacturer and exporter of 400+ medicines to over 50 countries.
Ukraine FARM
Farmsintez ao Logo
Produces APIs & hospital drugs for oncology & specialty diseases; offers contract services.
Russian Federation LIFE

Talk to a Data Expert

Have a question? We'll get back to you promptly.